Shionogi & Co., Ltd.
Clinical trials sponsored by Shionogi & Co., Ltd., explained in plain language.
A Japanese pharmaceutical company focused on infectious diseases and pain management.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New RSV drug trial aims to protect vulnerable adults Results expected Dec 2026 (estimated)
- New drug combo targets breathing pauses in sleep apnea Results expected Dec 2026 (estimated)
- Can a new pill shorten COVID-19 symptoms? Results expected Jul 2027 (estimated)
- New pill could boost breathing in pompe disease – early trial underway Results expected Aug 2027 (estimated)
-
ALS drug trial halted early: what we know about oral edaravone
Disease control Stopped earlyThis study tested two doses of oral edaravone in 202 people with ALS to see if it could slow disease progression. Participants were followed for up to 48 weeks. The trial was terminated early, so the full results are not available.
Phase 3 • Sponsor: Shionogi • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
ALS drug trial halted: oral Edaravone's promise unfulfilled
Disease control Stopped earlyThis study tested an oral form of edaravone in 384 adults with ALS to see if it could slow the disease's progression over 48 weeks. Participants were randomly assigned to different dosing schedules. The trial was terminated early, and results are not yet fully available.
Phase 3 • Sponsor: Shionogi • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Stroke drug study halted early: new dosing regimen tested in 17 patients
Disease control Stopped earlyThis study aimed to find the best dose of MCI-186 for people who had an acute ischemic stroke. It compared a new way of giving the drug (a bolus followed by continuous infusion) with the standard twice-daily dosing for 14 days. The trial was terminated early and included only 17 …
Phase 2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC